Experimental Cancer Drug Reduces Deadly Brain Tumor Within Days, Study Shows Promising Results
A groundbreaking study from Mass General Cancer Center, published in The New England Journal of Medicine, reports promising early results for a novel CAR-T cell therapy targeting Glioblastoma. The phase 1 INCIPIENT Trial evaluated an experimental treatment called CARv3-TEAM-E T cell therapy in patients with recurrent disease.
Glioblastoma is one of the most aggressive brain tumors, with poor survival rates and limited treatment options. Standard approaches-surgery, radiation, and chemotherapy-often fail due to tumour heterogeneity, where cancer cells vary widely within the same tumour, making targeted therapies less effective.
CAR-T Cell Therapy works by modifying a patient’s own T cells to recognize and attack cancer cells. While successful in blood cancers, its application in solid tumors like glioblastoma has been challenging. This new approach aims to overcome those barriers.
In the study, three patients aged 57 to 74 received the therapy after standard treatments had failed. All showed rapid tumor reduction. One patient experienced near-complete tumor disappearance within five days. Another had over 60% tumor shrinkage lasting more than six months, while the third showed significant but temporary improvement. Although tumors eventually progressed in all cases, the speed and magnitude of response mark a major advance.
The treatment was generally well tolerated, with manageable side effects such as fever and temporary neurological symptoms. Patients were closely monitored and safely discharged.
Researchers are now focused on improving durability through strategies like repeated infusions, combination therapies, and enhancing T cell persistence.
While still experimental, this therapy represents a significant step forward. It offers new hope for patients with glioblastoma and may pave the way for more effective, personalized cancer treatments in the future.
REFERENCE: Bryan D. Choi, Elizabeth R. Gerstner, et al.; Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma; The New England Journal of Medicine; DOI: 10.1056/NEJMoa2314390
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.